8-K: INmune Bio Receives Favorable Patentability Opinion for CORDStrom Platform Technology

INmune Bio Inc. announced a favorable patentability opinion from the United States Patent and Trademark Office for its CORDStrom platform technology.

Summary

• INmune Bio Inc. has received a favorable patentability opinion from the USPTO for its CORDStrom platform.
• The opinion covers all claims in the international patent application PCT/US25/17028.
• The USPTO, acting as the International Search Authority, confirmed that all claims possess novelty, inventive step, and industrial applicability.
• CORDStrom is a next-generation mesenchymal stromal cell (MSC) product comprising pooled, culture-expanded human umbilical cord-derived MSCs.
• The company plans to accelerate prosecution of the U.S. national application via the Patent Prosecution Highway (PPH).
• A recent Phase 2 trial showed CORDStrom demonstrated reductions in pain and itch, with early signals of improved skin integrity and disease activity.
• The patent, once granted, will provide IP exclusivity for the CORDStrom product platform through at least 2045, subject to patent term extension or adjustments.

Sentiment

Score: 8

Explanation: The announcement is positive due to the favorable patentability opinion and promising Phase 2 trial data. The potential for long-term IP exclusivity further boosts the sentiment.

Positives

• The favorable patentability opinion from the USPTO validates the novelty and potential of the CORDStrom platform.
• The potential IP exclusivity through at least 2045 provides a long-term competitive advantage.
• The Phase 2 trial results showing reductions in pain and itch suggest therapeutic potential.
• The CORDStrom platform offers batch-to-batch consistency and tunability across multiple disease indications.

Risks

• CORDStrom is still in clinical trials and has not been approved by the FDA or any regulatory body.
• There is no assurance that CORDStrom will be approved by the FDA or any regulatory body or that any specific results will be achieved.
• The company's ability to produce more drug for clinical trials is a risk.
• The availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization is a risk.

Future Outlook

INmune Bio plans to accelerate prosecution of the U.S. national application via the Patent Prosecution Highway (PPH). The company views this development as a pivotal step toward unlocking the full therapeutic and commercial potential of its MSC platform.

Management Comments

• 'We are encouraged with the examination results and the examiners favorable opinion of patentability concerning all submitted claims,' said Joshua Schoonover, General Counsel of INmune Bio.

Industry Context

The announcement positions INmune Bio as a player in the cell therapy space, specifically with its CORDStrom platform. The focus on pooled, culture-expanded human umbilical cord-derived MSCs differentiates it from traditional MSC products. The favorable patentability opinion strengthens its competitive position in the market.

Comparison to Industry Standards

• Companies like Mesoblast and Osiris Therapeutics (now part of Smith & Nephew) are key players in the MSC therapy field.
• CORDStrom's approach of using pooled, culture-expanded hucMSCs aims to address the batch-to-batch variability issues often seen in MSC therapies, a common challenge in the industry.
• The potential patent exclusivity until 2045, if granted, would provide a significant competitive advantage compared to companies relying on less protected MSC technologies.

Stakeholder Impact

• Shareholders may react positively to the news of the favorable patentability opinion and potential IP exclusivity.
• The positive Phase 2 trial data could lead to increased investor confidence.
• Patients with inflammatory and degenerative diseases may benefit from the development of CORDStrom as a potential therapy.

Next Steps

• INmune Bio plans to accelerate prosecution of the U.S. national application via the Patent Prosecution Highway (PPH).

Key Dates

Keywords

CORDStrom, INmune Bio, Patentability Opinion, Mesenchymal Stromal Cells, MSC, PCT/US25/17028, USPTO, Intellectual Property, Cell Therapy, hucMSCs